Asgard’s CEO on the EUR 30 million Series A financing
Asgard Therapeutics is a biotech based in Lund developing an immune “Trojan horse” to defeat cancer. The company recently announced a € 30 million Series A financing to advance its cell reprogramming platform for immuno-oncology. Asgard’s CEO and co-founder Cristiana Pires stopped by the BioStock Studio to tell us all about it.
Watch the interview here:
